{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:32:06Z","timestamp":1765279926517,"version":"3.46.0"},"posted":{"date-parts":[[2025,12,4]]},"group-title":"Oncology","reference-count":41,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\n                    <jats:italic>BAP1<\/jats:italic>\n                    -tumor predisposition syndrome (\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS) is associated with four main cancers: uveal melanoma, cutaneous melanoma, malignant mesothelioma, and renal cell carcinoma. However, there are additional cancers found more rarely in\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS patients. The aim of this study was to investigate the association, clinical, and pathologic characteristics of meningioma in\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    We conducted a retrospective chart review of meningiomas in two independent cohorts of patients with germline\n                    <jats:italic>BAP1<\/jats:italic>\n                    pathogenic or likely pathogenic (P\/LP) variants at The Ohio State University Wexner Medical Center and at the Memorial Sloan Kettering Cancer Center from October 1\n                    <jats:sup>st<\/jats:sup>\n                    , 2010 date to April 21\n                    <jats:sup>st<\/jats:sup>\n                    , 2025. Additionally, we conducted a literature review of meningioma case studies for individuals with germline\n                    <jats:italic>BAP1<\/jats:italic>\n                    (P\/LP) variants.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    In a cohort of 237 subjects with\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS, we identified 6.8% (16\/237) with history of meningiomas. The average age of diagnosis was 45.8 years (17-71). For patients with available pathology, 61.5% (8\/13) of the tumors were grade II\/III. Patients with available tumor tissue 83.3% (5\/6) showed evidence of\n                    <jats:italic>BAP1<\/jats:italic>\n                    biallelic inactivation. Family history of meningioma was reported in 18.8% (3\/16) of patients. Three cases of meningioma were identified during meningioma surveillance imaging. Published cases were consistent with the early age of onset, high-grade tumors, and clinical phenotype of tumors.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>\n                    This study provides additional evidence that high-grade brain and spinal meningiomas are part of the clinical spectrum of\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS. Craniospinal imaging surveillance in the\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS population should be considered starting around puberty, enabling early detection and management for individuals with\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>High frequency of patients in our BAP1-TPDS cohort had meningiomas (6.8%)<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>BAP1-TPDS meningiomas had rhabdoid and papillary histologic subtypes and high WHO grades<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>These patients were diagnosed at a younger age compared to the average population<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>There was a female predominance of meningioma in BAP1-TPDS patients<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>BAP1-TPDS related meningiomas are at risk for higher rates of local recurrence, particularly rhabdoid histology<\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Importance of the Study<\/jats:title>\n                  <jats:p>\n                    BAP1-tumor predisposition syndrome (\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS) is a rare syndrome which is associated with four cancers: uveal melanoma, cutaneous melanoma, malignant mesothelioma, and renal cell carcinoma. However, our group has observed additional cancers in these patients, including meningioma. Here, we present a retrospective chart review of 16 patients with germline pathogenic\n                    <jats:italic>BAP1<\/jats:italic>\n                    variants and meningioma, representing 6.8% of our entire cohort of\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS cases. We report that BAP1-TPDS patients are at higher risk of developing high-grade meningiomas and are diagnosed at an earlier age than the general population. Three meningiomas and one meningothelial cyst were observed during surveillance imaging in asymptomatic patients. Patient and family cancer history included other\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS associated cancers, but only three patients had relatives with meningioma. Our findings indicate a need for routine craniospinal imaging in\n                    <jats:italic>BAP1<\/jats:italic>\n                    -TPDS patients, and surveillance should include patients without family history of meningioma and patients under the age of 30.\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2025.12.04.25341363","type":"posted-content","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T18:00:29Z","timestamp":1765216829000},"source":"Crossref","is-referenced-by-count":0,"title":["High Frequency and Unique Subtypes of Meningioma in Patients with BAP1 Tumor Predisposition Syndrome"],"prefix":"10.64898","author":[{"given":"Kaylee A.","family":"Ramsey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-5331","authenticated-orcid":false,"given":"Lindsey","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6827-0552","authenticated-orcid":false,"given":"Olivia B.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Latham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4133-7895","authenticated-orcid":false,"given":"Saman S.","family":"Ahmadian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell R.","family":"Lonser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-0129","authenticated-orcid":false,"given":"Joshua D.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-7408","authenticated-orcid":false,"given":"Maria I.","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5636-4968","authenticated-orcid":false,"given":"Colleen M.","family":"Cebulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-7894","authenticated-orcid":false,"given":"Mohamed H.","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025120903150183000_2025.12.04.25341363v1.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-00709-4"},{"key":"2025120903150183000_2025.12.04.25341363v1.2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.11.24"},{"key":"2025120903150183000_2025.12.04.25341363v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3459"},{"key":"2025120903150183000_2025.12.04.25341363v1.4","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2011-100156"},{"key":"2025120903150183000_2025.12.04.25341363v1.5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.2330"},{"key":"2025120903150183000_2025.12.04.25341363v1.6","unstructured":"Pilarski R , Byrne L , Carlo MI , et al (1993) BAP1 Tumor Predisposition Syndrome. In: Adam MP , Feldman J , Mirzaa GM , et al (eds) GeneReviews\u00ae. University of Washington, Seattle, Seattle (WA)"},{"key":"2025120903150183000_2025.12.04.25341363v1.7","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e32835d0efb"},{"key":"2025120903150183000_2025.12.04.25341363v1.8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy171"},{"key":"2025120903150183000_2025.12.04.25341363v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2015.12.007"},{"key":"2025120903150183000_2025.12.04.25341363v1.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035295"},{"key":"2025120903150183000_2025.12.04.25341363v1.11","unstructured":"Alruwaili AA , De Jesus O (2025) Meningioma. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"2025120903150183000_2025.12.04.25341363v1.12","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106"},{"key":"2025120903150183000_2025.12.04.25341363v1.13","doi-asserted-by":"publisher","DOI":"10.3171\/2010.3.JNS091971"},{"key":"2025120903150183000_2025.12.04.25341363v1.14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01522"},{"key":"2025120903150183000_2025.12.04.25341363v1.15","doi-asserted-by":"publisher","DOI":"10.3171\/2014.7.JNS131644"},{"key":"2025120903150183000_2025.12.04.25341363v1.16","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now235"},{"key":"2025120903150183000_2025.12.04.25341363v1.17","doi-asserted-by":"publisher","DOI":"10.1111\/cge.12630"},{"key":"2025120903150183000_2025.12.04.25341363v1.18","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01040-2"},{"key":"2025120903150183000_2025.12.04.25341363v1.19","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox094"},{"key":"2025120903150183000_2025.12.04.25341363v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.06.227"},{"key":"2025120903150183000_2025.12.04.25341363v1.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02161-7"},{"key":"2025120903150183000_2025.12.04.25341363v1.22","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov247"},{"key":"2025120903150183000_2025.12.04.25341363v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3947"},{"key":"2025120903150183000_2025.12.04.25341363v1.24","doi-asserted-by":"publisher","DOI":"10.3390\/cells13161348"},{"key":"2025120903150183000_2025.12.04.25341363v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189267"},{"key":"2025120903150183000_2025.12.04.25341363v1.26","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Kidney Cancer V3.2025 \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed 4\/8\/2025. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"2025120903150183000_2025.12.04.25341363v1.27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.721712"},{"key":"2025120903150183000_2025.12.04.25341363v1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.765"},{"key":"2025120903150183000_2025.12.04.25341363v1.29","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now235"},{"key":"2025120903150183000_2025.12.04.25341363v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.09.011"},{"key":"2025120903150183000_2025.12.04.25341363v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2024.100980"},{"key":"2025120903150183000_2025.12.04.25341363v1.32","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5503505"},{"key":"2025120903150183000_2025.12.04.25341363v1.33","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-023-01505-0"},{"key":"2025120903150183000_2025.12.04.25341363v1.34","doi-asserted-by":"crossref","unstructured":"Solomon DA , Pekmezci M (2020) Chapter 5 - Pathology of meningiomas. In: McDermott MW (ed) Handbook of Clinical Neurology. Elsevier, pp 87\u201399","DOI":"10.1016\/B978-0-12-804280-9.00005-6"},{"key":"2025120903150183000_2025.12.04.25341363v1.35","doi-asserted-by":"publisher","DOI":"10.3171\/2014.7.JNS131644"},{"key":"2025120903150183000_2025.12.04.25341363v1.36","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf105"},{"key":"2025120903150183000_2025.12.04.25341363v1.37","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now235"},{"key":"2025120903150183000_2025.12.04.25341363v1.38","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/nlv006"},{"key":"2025120903150183000_2025.12.04.25341363v1.39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01523"},{"key":"2025120903150183000_2025.12.04.25341363v1.40","unstructured":"Pilarski R , Byrne L , Carlo MI , et al (1993) BAP1 Tumor Predisposition Syndrome. In: Adam MP , Feldman J , Mirzaa GM , et al (eds) GeneReviews\u00ae. University of Washington, Seattle, Seattle (WA)"},{"key":"2025120903150183000_2025.12.04.25341363v1.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.04.041"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2025.12.04.25341363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:15:10Z","timestamp":1765278910000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2025.12.04.25341363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":41,"URL":"https:\/\/doi.org\/10.64898\/2025.12.04.25341363","relation":{},"subject":[],"published":{"date-parts":[[2025,12,4]]},"subtype":"preprint"}}